BioPharmSignal logoBioPharmSignal

Biotech News

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsConference / presentation

PASADENA, Calif. --(BUSINESS WIRE)--Sep. 3, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: 2026 Cantor Global Healthcare Conference – September 9-11, 2026 Type: Fireside Chat Presentation

Related news

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

PTCTPTC Therapeutics, Inc.2026-08-27 12:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

ETONEton Pharmaceuticals2026-08-27 10:50 EST

Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

ARWRArrowhead Pharmaceuticals2026-09-15 11:30 EST

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

RAREUltragenyx Pharmaceutical2026-06-03 20:30 EST

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

PHARPharming Group2026-06-02 06:00 EST

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

EDITEditas Medicine2026-05-28 20:01 EST

Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference

View all latest news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

ARWRArrowhead Pharmaceuticals2026-09-15 11:30 EST

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

ARWRArrowhead Pharmaceuticals2026-08-30 15:30 EST

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

ARWRArrowhead Pharmaceuticals2026-08-17 13:33 EST

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Stock data

Close
67.74 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States